1-乙基-1H-苯并三唑 | 16584-05-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 1-乙基-1H-苯并三唑
• 英文名称: 1-ethylbenzotriazole
• 英文别名: 1-Ethylbenzotriazol；1-ethyl-1H-benzotriazole；1-Aethylbenzotriazol；Ethylbenzotriazol
• CAS: 16584-05-7
• 化学式: C₈H₉N₃
• mdl: MFCD00464850
• 分子量: 147.18
• InChiKey: VGCWCUQMEWJQSU-UHFFFAOYSA-N

物化性质

• 沸点：
  157-161 °C(Press: 18 Torr)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.7
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-乙基-1H-苯并三唑 在 溴 、 硝酸 作用下， 生成 1-ethyl-4,5,6,7-tetrabromo-1H-benzotriazole
  参考文献：
  名称：

  Wiley; Hussung, Journal of the American Chemical Society, 1957, vol. 79, p. 4395,4399

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(氯甲基)-1H-苯并三唑 以 甲醇 、 乙醚 、 甲苯 为溶剂， 反应 1.0h， 生成 1-乙基-1H-苯并三唑
  参考文献：
  名称：

  Reactions of 1-(.alpha.-alkoxyalkyl)- and 1-(.alpha.-(aryloxy)alkyl)benzotriazoles with the Grignard reagents. A new and versatile method for the preparation of ethers

  摘要：

  DOI：

  10.1021/jo00287a011

文献信息

• NOVEL POLYMORPHIC FORMS OF VORTIOXETINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
  申请人：ALEMBIC PHARMACEUTICALS LIMITED

  公开号：US20170189394A1

  公开（公告）日：2017-07-06

  The present invention provides polymorphic forms of Vortioxetine of and its pharmaceutically acceptable salts. Specifically the present invention relates to the novel crystalline forms of Vortioxetine or its pharmaceutically acceptable salts. Moreover, the present invention also provides an amorphous form of Vortioxetine hydrobromide and a stable amorphous co-precipitate of Vortioxetine hydrobromide with pharmaceutically acceptable excipients.

  本发明提供了氟美沙辛的多态形式及其药用盐。具体地，本发明涉及氟美沙辛或其药用盐的新型晶体形式。此外，本发明还提供了氟美沙辛盐酸盐的非晶形式以及氟美沙辛盐酸盐与药用可接受的辅料形成的稳定非晶共沉淀物。
• [EN] TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE<br/>[FR] INHIBITEURS, À BASE DE TRIAZOLOPYRIDINE, DE LA MYÉLOPEROXYDASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017040449A1

  公开（公告）日：2017-03-09

  The present invention provides compounds of Formula (I): wherein A is as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.

  本发明提供了化合物的结构式（I）：其中A如规范中定义，并包括任何此类新化合物的组合物。这些化合物是髓过氧化物酶（MPO）抑制剂和/或嗜酸性粒细胞过氧化物酶（EPX）抑制剂，可用作药物。
• PROCESS OF MAKING CFTR MODULATORS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20210047345A1

  公开（公告）日：2021-02-18

  The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

  该披露提供了合成化合物I及其药用可接受的盐的过程。
• PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS
  申请人：Bergmann John E.

  公开号：US20080300240A1

  公开（公告）日：2008-12-04

  Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette syndrome, schizophrenia, delusional disorders, drug-induced psychosis and panic and obsessive-compulsive disorders. The compounds have the general structure: wherein m, n, p, x, R, R 1 , R 2 , R 3 , R 4 , R 5 , A and B, are defined herein, including pharmaceutically acceptable salts, stereoisomers, solvates or prodrugs thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for inhibiting PDE 10 in a warm-blooded animal in need of the same.

  抑制PDE10的化合物已被披露，对治疗包括（但不限于）精神病、焦虑、运动障碍和/或神经系统疾病（如帕金森病、亨廷顿病、阿尔茨海默病、脑炎、恐惧症、癫痫、失语症、贝尔氏面瘫、脑瘫、睡眠障碍、疼痛、抽动症、精神分裂症、妄想症、药物诱发的精神病和恐慌以及强迫症）多种疾病具有用途。这些化合物具有一般结构： 其中m、n、p、x、R、R1、R2、R3、R4、R5、A和B在此定义，包括药学上可接受的盐、立体异构体、溶剂合物或其前药。还披露了含有本发明化合物的组合物，与药学上可接受的载体结合，以及与使用这些化合物抑制需要同样的PDE10的温血动物相关的方法。
• Photochemistry of Benzotriazoles: Generation of 1,3-Diradicals and Intermolecular Cycloaddition as a New Route toward Indoles and Dihydropyrrolo[3,4-b]Indoles
  作者：Nader Al-Jalal、Maher Ibrahim、Nouria Al-Awadi、Mohamed Elnagdi、Yehia Ibrahim

  DOI：10.3390/molecules191220695

  日期：——

  Irradiation of benzotriazoles 1a–e at λ = 254 nm in acetonitrile solution generated the corresponding 1,3-diradicals which underwent intermolecular cycloaddition with maleimides to afford the corresponding dihydropyrrolo[3,4-b]indoles and with acetylene derivatives to afford indoles as the major products. This offers an interesting and simple access to such ring systems of potential synthetic and biological

  在乙腈溶液中以 λ = 254 nm 照射苯并三唑 1a-e 产生相应的 1,3-双自由基，它们与马来酰亚胺进行分子间环加成反应，得到相应的二氢吡咯并 [3,4-b] 吲哚，并用乙炔衍生物得到吲哚作为主要产品。这提供了对具有潜在合成和生物学意义的此类环系统的有趣且简单的访问。光产物的结构是通过光谱和单晶 X 射线晶体学确定的。

表征谱图